ω‑3 fatty acids in atherosclerotic cardiovascular disease (Review)
- Authors:
- Published online on: April 19, 2024 https://doi.org/10.3892/br.2024.1782
- Article Number: 94
-
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is one of the most common chronic diseases in the world. Epidemiological evidence and clinical trials have shown that ω‑3 fatty acids have a variety of promoting effects in reducing the risk of ASCVD, but different conclusions of large randomized controlled trials make their clinical use in the prevention and treatment of ASCVD controversial. The present review focuses on the pharmacological mechanism, clinical trials and evidence value of clinical applications of ω‑3 fatty acids in order to provide theoretical and practical evidence for the clinical application strategy, and follow‑up research and development of ω‑3 fatty acids as anti‑ASCVD drugs.
